NervGen Pharma Corp.NervGen Pharma Corp.NervGen Pharma Corp.

NervGen Pharma Corp.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪112.68 M‬USD
−0.27USD
‪−16.89 M‬USD
0.00USD
‪54.03 M‬
Beta (1Y)
−0.40

About NERVGEN PHARMA CORP


CEO
Michael Kelly
Headquarters
Vancouver
Founded
2017
FIGI
BBG00NQ5C0K3
NervGen Pharma Corp. operates as a clinical stage biotech company. It provides development of treatment that enables the nervous system to repair itself following damage, whether due to injury or disease. The company was founded by Harold Punnett and William Joseph Radvak on January 19, 2017 and is headquartered in Vancouver, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NGENF is 1.79 USD — it has increased by 6.92% in the past 24 hours. Watch NervGen Pharma Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange NervGen Pharma Corp. stocks are traded under the ticker NGENF.
NGENF stock has fallen by −10.53% compared to the previous week, the month change is a 1.19% rise, over the last year NervGen Pharma Corp. has showed a 27.62% increase.
We've gathered analysts' opinions on NervGen Pharma Corp. future price: according to them, NGENF price has a max estimate of 2.93 USD and a min estimate of 2.93 USD. Watch NGENF chart and read a more detailed NervGen Pharma Corp. stock forecast: see what analysts think of NervGen Pharma Corp. and suggest that you do with its stocks.
NGENF reached its all-time high on Feb 8, 2024 with the price of 2.99 USD, and its all-time low was 0.55 USD and was reached on Mar 25, 2020. View more price dynamics on NGENF chart.
See other stocks reaching their highest and lowest prices.
NGENF stock is 12.35% volatile and has beta coefficient of −0.40. Track NervGen Pharma Corp. stock price on the chart and check out the list of the most volatile stocks — is NervGen Pharma Corp. there?
Today NervGen Pharma Corp. has the market capitalization of ‪112.67 M‬, it has increased by 3.43% over the last week.
Yes, you can track NervGen Pharma Corp. financials in yearly and quarterly reports right on TradingView.
NervGen Pharma Corp. is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
NGENF earnings for the last quarter are −0.05 USD per share, whereas the estimation was −0.05 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about NervGen Pharma Corp. earnings.
NGENF net income for the last quarter is ‪−3.86 M‬ USD, while the quarter before that showed ‪−5.72 M‬ USD of net income which accounts for 32.46% change. Track more NervGen Pharma Corp. financial stats to get the full picture.
No, NGENF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NGENF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NervGen Pharma Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NervGen Pharma Corp. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NervGen Pharma Corp. stock shows the buy signal. See more of NervGen Pharma Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.